ETFs Are Net Sellers of Clorox (CLX) on Nov. 2

ETFs were net sellers of Clorox (CLX) on Nov. 2, with RDIV reducing its stake by 99.92% and selling $21.1 million worth of shares. Total net ETF selling amounted to $14.0 million, ending a four-day buying streak. Clorox has a market cap of $11.3 billion, a P/E of 16.89, and a dividend yield of 5.23%.

Original reporting
Published Nov 4, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ETFs Are Net Sellers of Clorox (CLX) on Nov. 2 — source image
Decision brief

The 30-second read

$CLXBearishLow
01

Why it matters

ETF net selling may create short‑term downside risk, but fundamentals remain stable.

02

Market read

ETF flow data provides a modest, short‑term signal for CLX traders.

03

What to watch

Potential hidden buying from other funds not captured in the snapshot.

Relevance 4/10Novelty 3/10Timing: Monday

Background

Clorox (CLX) is a $11.3 B market‑cap consumer‑defensive stock with a 5.23% dividend yield.

Company-level read

Ticker impact

$CLXBearishMedium confidence
Context

ETFs sold a net $14.0 million of Clorox shares on Monday, with RDIV alone shedding $21.1 million.

Expected impact

downward pressure as the market prices in the net selling

Evidence & confidence

ETF outflows of $14 M represent a notable short‑term supply increase; no offsetting buying pressure was reported.

Market effects

Limited; reflects a brief shift in consumer‑defensive ETF positioning.

US equity market only.

Low.

Counterpoint

If the sell‑off is temporary, CLX could rebound on its solid dividend yield.

Key entities

  • RDIV

    Largest seller, offloaded $21.1 M of CLX.

  • XLP

    Sold $0.9 M of CLX.

  • SPHD

    Sold $0.3 M of CLX.

Related articles

$CLXMedAI 8/10

Why is Clorox stock climbing today?

Clorox (CLX) stock rose 1.2% in pre-market trading after reporting fiscal Q1 earnings of $1.55 per share, beating estimates by 45%, with revenue of $1.91B. Sales increased 33% YoY, driven by the GOJO acquisition and organic growth. Analysts upgraded price targets (Evercore ISI to $99, Wells Fargo to $90, JPMorgan to $86), but Goldman Sachs maintained a Sell rating with a $74 target. Management warned of higher input costs and adjusted EPS guidance downward.

$CLXHighAI 8/10

Clorox Co (CLX) (Q1 2027) Earnings Call Highlights: Record Cost Savings and GoJo

Clorox (CLX) reported Q1 2027 earnings, with CEO Linda Rendell and CFO Kevin Bellet discussing organic sales growth of 3.5% to 4.5%, including ERP benefits. They highlighted record cost savings, targeted pricing, and market share improvements in home care and Brita. GoJo synergies are progressing faster than expected, with revised EPS estimates. The company aims for long-term gross margin of 43% to 44% and operating margin of 18%.

$CLXMed

Clorox (CLX) Q1 2027 Earnings Call Transcript

Clorox (CLX) reported Q1 2027 earnings, updating its outlook to reflect $240M in input cost inflation, driven by commodities and transportation. The company expects organic sales growth of 3.5% to 4.5% for the year, with a flat to slightly positive performance in the back half. Clorox also announced Fabian Garcia as its next CEO, effective January. The company is implementing cost savings and targeted pricing to mitigate inflationary pressures.

$CLXMed

Clorox Q1 Earnings Call Highlights

Clorox (CLX) maintained its fiscal-year organic-sales-growth outlook of 3.5% to 4.5%, with Q2 expected to range from flat to down 2%. The company reported share gains in home care, Brita, and Hidden Valley Ranch, while Kingsford and cat litter faced challenges. Clorox is prioritizing pricing, innovation, and GOJO integration, with Fabian Garcia appointed as the next CEO. The company expects positive adjusted EPS impact from synergies in fiscal 2027.